International biotech company tackling diabetes chooses Leeds hub for expansion

An Israeli bio-technology company has chosen a Leeds hub as the base for its international expansion.

Betalin Therapeutics has announced that Nexus, the innovation hub at the University of Leeds, will be its new base as it develops the next stage of its diabetes treatment.

The treatment consists of a cell-therapy solution, which essentially creates a faux pancreas to provide insulin to diabetes sufferers.

Dr Nikolai Kunicher, CEO of Betalin Therapeutics, commented: “The move to Nexus is a major step forward for us.

“I visited Nexus last year and was extremely impressed with the team as well as the proposition.

“They have been so supportive and helpful across every aspect of our membership, communicating – as we all are currently – through video-links and telephone discussions.

“Leeds has an international reputation for its strengths in healthcare and medical technology and as the University of Leeds’ innovation hub, Nexus gives us access to vital academic skills as well as support for our growing business.

“We’re taking office space at Nexus with plans to add laboratory space as we grow our team of researchers and business developers and we’re really looking forward to being there in person rather than virtually.”

Dr Martin Stow, Nexus director, said: “We’re extremely honoured and very proud that Betalin Therapeutics has chosen Nexus as its base for the next stage of its international expansion.

“The company is set to take the treatment and cure for diabetes to the next level, with novel technology which could benefit millions of insulin-dependent people worldwide.

“We’re delighted they are joining our growing Nexus community and further strengthening the global reputation of Leeds as a major centre for healthcare and medical technology.”